



STATE OF OKLAHOMA
OKLAHOMA HEALTH CARE AUTHORITY

OHCA 2015-21

September 23, 2015

RE: Molecular Pathology Prior Authorization—Effective November 1, 2015

Dear Provider,

Beginning November 1, 2015, the Oklahoma Health Care Authority (OHCA) will require prior authorization (PA) for the following molecular pathology CPT codes:

- 81370: HLA Class I and II typing, low resolution (e.g., antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1
- 81371: HLA-A, -B, and -DRB1/3/4/5 (e.g., verification typing)
- 81372: HLA Class I typing, low resolution (e.g., antigen equivalents); complete (HLA-A, -B, and -C)
- 81373: one locus (e.g., HLA-A, -B, or -C), each
- 81374: one antigen equivalent (e.g., B*27), each
- 81375: HLA Class II typing, low resolution (e.g., antigen equivalents); HLA-DRB1/3/4/5 and -DQB1
- 81376: one locus (e.g., HLA-DRB1/3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each
- 81377: one antigen equivalent, each
- 81378: HLA Class I and II typing, high resolution (i.e., alleles or allele groups), HLA-A, -B, -C, and -DRB1
- 81379: HLA Class I typing, high resolution (i.e., alleles or allele groups); complete (HLA-A, -B, and -C)
- 81380: one locus (e.g., HLA-A, -B, or -C), each
- 81381: one allele or allele group (e.g., B*57:01P), each
- 81382: HLA Class II typing, high resolution (i.e., alleles or allele groups); one locus (e.g., HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQB1, -DQA1, -DPB1, or -DPA1), each
- 81383: one allele or allele group (e.g., HLA-DQB1*06:02P), each

OHCA requires the submission of all of the following documents for PA review:

1. HCA-13A Prior Authorization Form Cover Sheet
2. HCA-12A Prior Authorization Form
3. Objective clinical records supporting the medical necessity of the request

OHCA considers the use of the tests described above to be medically necessary for purposes including organ and tissue compatibility testing, diagnosis of individuals with clinical features of specific autoimmune disorders, and avoidance of hypersensitivity reactions when the FDA-

approved drug label requires testing. As a reminder, OHCA does not consider pharmacogenetic panel testing to be medically necessary.

If you have any questions regarding PA forms and documentation, please contact OHCA's Medical Authorization Unit at (800) 522-0114. If you have questions regarding OHCA's coverage of molecular pathology CPT codes, please contact Alison Martinez, Ph.D. at alison.martinez@okhca.org. Thank you for the services you provide to our SoonerCare and Insure Oklahoma members.

Sincerely,

A handwritten signature in black ink that reads "Garth L. Splinter, MD". The signature is written in a cursive style with a clear "MD" at the end.

Garth L. Splinter, MD
State Medicaid Director